BioNTech earnings 3/30 pre-marketBioNTech Q4 December 21' earnings are on 3/30 pre-market 6:45am. BioNTech Se ADR (BNTX) reported Q3 September 2021 earnings of $14.56 per share on revenue of $7.2 billion. The consensus earnings estimate was $11.79 per share on revenue of $5.8 billion. Revenue grew 9,003.0% on a year-over-year basis. I'm long now because a P/E = 3.7 for a leading MRNA biotechnology company heading into earnings is a rare opportunity. Plus, I waited until today from the technical entry I planned on Friday. Here's levels on the 1-day chart:
Q4 December 21' Consensus:
P/E = 3.7
EPS = $8.45
Revenue = $4.48B
52 week high = $464
52 week low = $93
SMA200 = $217
SMA100 =$206
breakout = $179
R3 = $169
R2 = $159
R1 = $150
pivot = $140
S1 = $130
S2 = $120
S3 = $111
breakdown = $101
Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends...
*3x lucky 7s of trading*
7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet
7 Common mistakes:
+5% portfolio trades, capital risk management
Beware of analyst's motives
Emotions & Opinions
FOMO : bad timing, the market is ruthless, be shrewd
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation
7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big, organized desk
Reading books, playing chess
Sorted watch-list
Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
TTC - trend channel
AlertiT - notification
tickerTracker - MFI Oscillator
www.tradingview.com
22UA trade ideas
BNTX HIGH RISK TO REWARD SETUP YOU CAN'T MISSNews - Better than expected Q4 EPS and sales results, the company expects to authorize a shares repurchase program up to 1.5B over the next two years.
Levels -$195 is the next major resistance level.
$138 is the next major support level.
The stock is gapping up to $183 (pre-market).
The idea is to go long at the open when it will try to test the $183 support level and fail, then go long above the 5M bull flag pattern if it will happen.
BNTX LONG SETUPWe just finished Elliot wave 1-5 and ABC pattern, already bounced off of a strong demand zone and 71.8% fib zone we can enter right now but our R/R ratio is 1.7 since we missed first bounce, what we are looking for is a retrace to our entry point ant 71.8% fib zone and enter there. Also market made a gap at 182 zone which has to be filled. Also a gap at 325 zone, which also needs to be filled.
AROON: On a daily chart AROON already shows bullish momentum (Orange line above blue one)
Bollinger band: we already bounced off of a bottom Bollinger band which indicates bullish direction movement.
Entry:119 (We can enter right now but for better R/R I would suggest to wait for a retest at the entry zone, though it might not do that and we might miss a trade)
Invalidation: 79 ( Just below Demand zone )
Target 1: 292 (50% FIB ZONE)
Target 2: 325 (Second gap zone)
Ratio if we wait for retest: 4.38
Ratio if we enter right now: 1.75
Descending wedgeBNTX looks to be in a descending wedge and coming to its peak.
I have highlighted the red line horizontal resistance levels to watch in the event of a breakout.
Orange lines are the nPOC levels of interest.
Green line should be major support area at 120.
Descending wedge PT would be top of wedge.
no description neededno description needed no description needed no description needed no description needed no description needed no description needed no description needed no description neededno description needed no description needed no description needed no description needed no description needed no description needed no description needed no description neededno description needed no description needed no description needed no description needed no description needed no description needed no description needed no description needed
$BNTX; trading it 1/3 For 1/3, intraday trading ideas for options trading; not financial advice, 2 plans for red or green market day.
Break over 264 (entry, long), it can see 275-282 (exit)
Break below 251 (entry, short), it can see 233-240 (exit)
#options #daytrading
Option Trading 101:
Risk what you can lose (0.5%-5%)
Watch buyers and sellers (their interactions & sentiment, ex. exhaustion of buying or selling, etc.) in strikes that you’re watching & the ticker too; this is how YOU manage YOUR trade.
Consider following and checking out my prior posts, have a great one.
Biontech Analysis 22.12.2021Hello Traders,
welcome to this free and educational analysis.
I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities.
If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below.
I will personally reply to every single comment!
If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel.
Thank you for watching and I will see you tomorrow!
BNTX LONG +5, +30 +150 % channelI will buy Biontech after breaking through the turquoise bold line. In doing so, I will set a short stop lose at 0.4% below this line and will raise it over time. Next, I plan to buy after the next thin turquoise line is broken, if the indicators favor buying.
This is not a financial recommendation.
Take care.
$BNTX^ $BNTX will announce if its possible to revise their current vaccine to accommodate the new strain in 2 weeks and could redesign its vaccine within 6 weeks, with an aim to distribute it within 100 days.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Long BNTX Call OptionsBNTX appears to be breaking out on news from Europe in relation to COVID. Governments such as Austria are taking a much harder line and this should significantly increase demand (initial doses plus boosters).
Bought two sets of call options - Dec/17 and short term breakout Nov/26.